Multiple Myeloma
Conference Coverage
MM: First CAR T-Cell Therapy to Exhibit OS Benefit
CARTITUDE-4 study update indicated that CAR T-cell therapy improves overall survival in relapsed/refractory multiple myeloma.
News
Cancer Risk: Are Pesticides the New Smoking?
A recent study evaluated cancer risks in the US population using a model that accounts for pesticide use and adjusts for various factors.
Article
RVD With Weekly Bortezomib Has a Favorable Toxicity and Effectiveness Profile in a Large Cohort of US Veterans With Multiple Myeloma
Article
The First Patient in the Veteran Affairs System to Receive Chimeric Antigen Receptors T-cell Therapy for Refractory Multiple Myeloma and the Role of Intravenous Immunoglobulin in the Prevention of Therapy-associated Infections
Article
The First Female Patient in the Veteran Affairs System to Receive Chimeric Antigen Receptors (CAR) T-cell Therapy for Refractory Multiple Myeloma and the Role of CAR T-cell Therapy in Penta-refractory Disease
News
Do Clonal Hematopoiesis and Mosaic Chromosomal Alterations Increase Solid Tumor Risk?
Researchers analyzed whole genome sequencing data from 10,866 women in the WHI to explore possible associations between CHIP, mCA, and solid...
Commentary
Multiple Myeloma: New Treatments Aid Patient Subgroups
A leading Spanish blood cancer expert discusses the striking benefits of innovative new therapies for multiple myeloma.
News
Immunotherapy May Be Overused in Dying Patients With Cancer
“There are patients who are getting immunotherapy who shouldn’t,” according to a surgical oncologist from Yale.
News
Ancient Viruses in Our DNA Hold Clues to Cancer Treatment
Targeting remnants of a virus in our DNA could lead to more effective cancer treatment with fewer side effects.
News
Should Cancer Trial Eligibility Become More Inclusive?
A new study highlights the potential benefits of broadening eligibility criteria for clinical trials.
